Table 1 Study cohort overview
From: Cannabis smoking is associated with persistent epigenome-wide disruptions despite smoking cessation
Variable | Cannabis smoking status | |||
|---|---|---|---|---|
Never (n = 51) | Former (n = 32) | Current (n = 10) | p-value | |
Age (years) | 55.15 (48.06–62.60) | 57.94 (49.30–60.88) | 49.30 (47.41–54.98) | 0.255 |
Female sex, n (%) | 42 (82%) | 25 (78%) | 4 (40%) | 0.022 |
BMI (kg/m2) | 28.02 (25.45–31.03) | 27.05 (23.65–30.55) | 27.03 (20.57–28.62) | 0.364 |
Cannabis joint-years | NA | 1 (0.06—2.47) | 14 (8.01—36.47) | * 0.002 |
Tobacco cigarette smoking status |  |  |  |  < 0.001 |
 Never, n (%) | 35 (69%) | 10 (31%) | 1 (10%) |  |
 Former, n (%) | 3 (6%) | 3 (9%) | 5 (50%) |  |
 Current, n (%) | 13 (25%) | 19 (59%) | 4 (40%) |  |
COPD, n (%) | 11 (26%) | 7 (22) | 3 (30%) | 0.822 |
Asthma, n (%) | 20 (39%) | 13 (41%) | 4 (40%) |  ~ 1 |
Post-bronchodilator FEV1% Predicted | 87.47 (76.64—95.64) | 83.70 (69.23—93.59) | 72.24 (65.49—93.06) | 0.521 |
Post-bronchodilator FVC % Predicted | 99.12 (88.92—107.09) | 98.49 (84.31—108.61) | 91.98 (85.66—104.14) | 0.663 |
Post-bronchodilator FEV1/FVC (%) | 86.20 (79.34—89.98) | 85.31 (75.55—90.84) | 83.49 (72.76—88.11) | 0.735 |